These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37841251)

  • 1. Specific IgG glycosylation differences precede relapse in PR3-ANCA associated vasculitis patients with and without ANCA rise.
    Wojcik I; Wuhrer M; Heeringa P; Stegeman CA; Rutgers A; Falck D
    Front Immunol; 2023; 14():1214945. PubMed ID: 37841251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity.
    Lardinois OM; Deterding LJ; Hess JJ; Poulton CJ; Henderson CD; Jennette JC; Nachman PH; Falk RJ
    PLoS One; 2019; 14(2):e0213215. PubMed ID: 30818380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis.
    Kemna MJ; Plomp R; van Paassen P; Koeleman CAM; Jansen BC; Damoiseaux JGMC; Cohen Tervaert JW; Wuhrer M
    EBioMedicine; 2017 Mar; 17():108-118. PubMed ID: 28169190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation.
    Wuhrer M; Stavenhagen K; Koeleman CA; Selman MH; Harper L; Jacobs BC; Savage CO; Jefferis R; Deelder AM; Morgan M
    J Proteome Res; 2015 Apr; 14(4):1657-65. PubMed ID: 25761865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies.
    Xu PC; Gou SJ; Yang XW; Cui Z; Jia XY; Chen M; Zhao MH
    BMC Immunol; 2012 Mar; 13():10. PubMed ID: 22404873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
    Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.
    Sandin C; Eriksson P; Segelmark M; Skogh T; Kastbom A
    Clin Exp Immunol; 2016 May; 184(2):208-15. PubMed ID: 26762653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in IgG Fc Glycosylation Are Associated with Outcome of Pediatric Meningococcal Sepsis.
    de Haan N; Boeddha NP; Ekinci E; Reiding KR; Emonts M; Hazelzet JA; Wuhrer M; Driessen GJ
    mBio; 2018 Jun; 9(3):. PubMed ID: 29921663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
    Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
    Front Immunol; 2020; 11():2053. PubMed ID: 33013868
    [No Abstract]   [Full Text] [Related]  

  • 12. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-neutrophil cytoplasmic antibodies predate symptom onset of ANCA-associated vasculitis. A case-control study.
    Berglin E; Mohammad AJ; Dahlqvist J; Johansson L; Eriksson C; Sjöwall J; Rantapää-Dahlqvist S
    J Autoimmun; 2021 Feb; 117():102579. PubMed ID: 33340843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.
    Osman MS; Tervaert JWC
    Curr Rheumatol Rep; 2019 Dec; 21(12):76. PubMed ID: 31879818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study.
    Hilhorst M; Arndt F; Joseph Kemna M; Wieczorek S; Donner Y; Wilde B; Thomas Epplen J; van Paassen P; Cohen Tervaert JW
    Arthritis Rheumatol; 2016 Jul; 68(7):1721-30. PubMed ID: 26866715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
    Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
    Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement.
    Kemna MJ; Cohen Tervaert JW; Broen K; Timmermans SAMEG; van Paassen P; Damoiseaux JGMC
    J Rheumatol; 2017 Apr; 44(4):473-481. PubMed ID: 28202741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.
    McAdoo SP; Hall A; Levy J; Salama AD; Pusey CD
    J Clin Rheumatol; 2012 Oct; 18(7):336-40. PubMed ID: 23047533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.